INCY
Incyte Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+3/100
Last price
112.73
▼ 1.40 (1.23%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
114.13
Prev close
114.13
Day high
114.97
Day low
111.67
Volume
2.46M
Market cap
$22.85B
P/E (TTM)
14.53
52W range
82.82 – 132.60
Day trading desk
Gap from prior close
+0.00%
Prior close 114.13
VWAP
112.97
-0.21% from price
Relative volume
2.79×
Unusually busy
Session range
3.32%
111.67 – 115.38
Position in range
29%
Near session low
ATR (14D)
3.34
2.96% of price
Prior day high
115.67
PDH
Prior day low
112.83
PDL
Bid / ask spread
—
Quote not published
Session volume
4.54M
Avg 1.63M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-8.50%
-10.4%
1M
-11.06%
-12.2%
3M
-3.86%
-8.4%
6M
+20.32%
+2.1%
YTD
+14.13%
-0.1%
1Y
+29.80%
+13.4%
3Y
+95.14%
+12.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on INCY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+356.19K
Net buying
Buy transactions
33
547.26K shares
Sell transactions
14
191.07K shares
Net transactions
+47
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
3.74M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | CAGNONI PABLO J Officer |
SELL | 23.22K | $2.80M | Direct |
| Sep 15, 26 | CAGNONI PABLO J Officer |
CONVERSION | 23.22K | $1.54M | Direct |
| Aug 19, 26 | CAGNONI PABLO J Officer |
SELL | 10.80K | $1.36M | Direct |
| Aug 12, 26 | CAGNONI PABLO J Officer |
SELL | 10.80K | $1.30M | Direct |
| Aug 5, 26 | MAYES PATRICK A Officer |
SELL | 2.21K | $273.65K | Direct |
| Aug 5, 26 | CAGNONI PABLO J President |
SELL | 10.64K | $1.31M | Direct |
| Aug 5, 26 | MAYES PATRICK A Officer |
CONVERSION | 2.21K | $234.98K | Direct |
| Aug 3, 26 | MAYES PATRICK A Officer |
SELL | 47.95K | $5.73M | Direct |
| Aug 3, 26 | MAYES PATRICK A Officer |
CONVERSION | 45.77K | $3.59M | Direct |
| Jul 31, 26 | CAGNONI PABLO J Officer |
SELL | 15.89K | $1.90M | Direct |
| Jul 16, 26 | ISSA MOHAMED KHAIRIE Officer |
STOCK | 7.86K | $0 | Direct |
| Jul 16, 26 | MAYES PATRICK A Officer |
STOCK | 5.92K | $0 | Direct |
| Jul 16, 26 | BASI RAMITPAL K Officer |
STOCK | 4.99K | $0 | Direct |
| Jul 16, 26 | GARDNER DAVID H Officer |
STOCK | 7.39K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER BROS ADVISORS L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
BAKER BROTHERS LIFE SCIENCES L P |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
CAGNONI PABLO J |
Officer | 183.20K | Sale |
HOPPENOT HERVE |
Director | 329.65K | Sale |
ISSA MOHAMED KHAIRIE |
Officer | 71.80K | Stock Award(Grant) |
IYENGAR VIJAY K |
Officer | 40.54K | Sale |
MAYES PATRICK A |
Officer | 61.44K | Sale |
MEURY WILLIAM |
Chief Executive Officer | 183.13K | Stock Award(Grant) |
STAMOULIS CHRISTIANA |
Chief Financial Officer | 125.76K | Stock Award(Grant) |
SWAIN PAULA J |
Officer | 106.48K | Stock Award(Grant) |
Fundamentals
Market cap$22.85B
Enterprise value$18.35B
Revenue (TTM)$5.82B
Gross profit$3.24B
EBITDA$1.94B
Net income$1.61B
EPS (TTM)$7.76
Free cash flow$1.18B
Total cash$4.54B
Total debt$38.27M
Book value / share$31.57
Shares outstanding202.70M
Float170.41M
Short % of float8.39%
Dividend yield0.00%
Beta (5Y)0.74
Valuation & profitability ratios
Trailing P/E14.53
Forward P/E12.89
PEG ratio10.82
Price / sales—
Price / book3.57
EV / revenue3.15
EV / EBITDA9.45
Gross margin55.66%
Operating margin41.90%
Profit margin27.71%
Return on equity30.67%
Return on assets16.83%
Debt / equity0.60
Current ratio4.59
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $5.14B | $4.24B | $3.70B | $3.39B | +21.2% |
| Operating revenue | $5.14B | $4.24B | $3.70B | $3.39B | +21.2% |
| Cost of revenue | $372.10M | $312.10M | $254.99M | $207.00M | +19.2% |
| Gross profit | $4.77B | $3.93B | $3.44B | $3.19B | +21.4% |
| Research & development | $2.05B | $2.61B | $1.63B | $1.59B | -21.4% |
| Selling, general & admin | $1.38B | $1.22B | $1.16B | $1.00B | +12.6% |
| Total operating expense | $3.43B | $3.83B | $2.79B | $2.60B | -10.5% |
| Operating income | $1.34B | $101.29M | $655.36M | $591.63M | +1,225.6% |
| Net interest income | $103.17M | $126.43M | $155.86M | $37.78M | -18.4% |
| Pre-tax income | $1.66B | $316.63M | $834.22M | $529.12M | +425.7% |
| Tax provision | $377.80M | $284.01M | $236.62M | $188.46M | +33.0% |
| Net income | $1.29B | $32.62M | $597.60M | $340.66M | +3,845.0% |
| Net income to common | $1.29B | $32.62M | $597.60M | $340.66M | +3,845.0% |
| Basic EPS | 6.59 | 0.16 | 2.67 | 1.53 | +4,018.8% |
| Diluted EPS | 6.41 | 0.15 | 2.65 | 1.52 | +4,173.3% |
| EBIT | $1.67B | $318.91M | $836.77M | $531.78M | +422.7% |
| EBITDA | $1.76B | $408.16M | $919.43M | $599.64M | +331.2% |
| Basic shares | 195.20M | 207.11M | 223.63M | 222.00M | -5.7% |
| Diluted shares | 200.70M | 210.53M | 225.93M | 223.96M | -4.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.10B | $1.69B | $3.21B | $2.95B | +83.5% |
| Cash & short-term investments | $3.58B | $2.16B | $3.66B | $3.24B | +65.9% |
| Accounts receivable | $1.02B | $853.15M | $743.56M | $644.88M | +20.1% |
| Inventory | $101.06M | $58.87M | $62.97M | $41.99M | +71.7% |
| Total current assets | $5.02B | $3.24B | $4.65B | $4.09B | +55.1% |
| Property, plant & equipment | $758.40M | $794.21M | $777.05M | $765.61M | -4.5% |
| Goodwill & intangibles | $250.13M | $269.40M | $279.14M | $284.81M | -7.2% |
| Total assets | $6.96B | $5.44B | $6.78B | $5.84B | +27.8% |
| Total current liabilities | $1.52B | $1.64B | $1.24B | $1.16B | -7.7% |
| Total debt | $40.41M | $43.54M | $38.29M | $41.46M | -7.2% |
| Total liabilities | $1.79B | $2.00B | $1.59B | $1.47B | -10.3% |
| Retained earnings | $213.77M | -$1.07B | $160.38M | -$437.21M | +119.9% |
| Shareholder equity | $5.17B | $3.45B | $5.19B | $4.37B | +49.9% |
| Working capital | $3.51B | $1.60B | $3.41B | $2.94B | +119.7% |
| Net tangible assets | $4.92B | $3.18B | $4.91B | $4.09B | +54.7% |
| Shares issued | 198.46M | 193.43M | 224.29M | 222.75M | +2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.29B | $32.62M | $597.60M | $340.66M | +3,845.0% |
| Depreciation & amortisation | $93.29M | $89.25M | $82.66M | $67.86M | +4.5% |
| Stock-based compensation | $249.35M | $266.06M | $215.89M | $188.42M | -6.3% |
| Change in working capital | -$527.16M | $138.24M | -$248.65M | $198.81M | -481.3% |
| Operating cash flow | $1.41B | $335.34M | $496.49M | $969.94M | +321.5% |
| Capital expenditure | -$83.87M | -$100.16M | -$47.49M | -$77.83M | +16.3% |
| Investing cash flow | -$102.61M | $157.52M | -$207.68M | -$78.54M | -165.1% |
| Share buybacks | $0 | -$2.00B | $0 | $0 | +100.0% |
| Financing cash flow | $101.04M | -$2.02B | -$20.03M | -$794.00K | +105.0% |
| Free cash flow | $1.33B | $235.17M | $449.00M | $892.11M | +465.4% |
| End cash position | $3.10B | $1.69B | $3.22B | $2.95B | +83.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.67B | $1.27B | $1.51B | $1.37B | $1.22B | +31.5% |
| Operating revenue | $1.67B | $1.27B | $1.51B | $1.37B | $1.22B | +31.5% |
| Cost of revenue | $105.00M | $104.50M | $121.10M | $99.00M | $78.80M | +0.5% |
| Gross profit | $1.57B | $1.17B | $1.39B | $1.27B | $1.14B | +34.3% |
| Research & development | $516.95M | $515.90M | $611.37M | $506.58M | $494.92M | +0.2% |
| Selling, general & admin | $351.70M | $328.10M | $390.40M | $329.10M | $331.00M | +7.2% |
| Total operating expense | $868.65M | $844.00M | $1.00B | $835.68M | $825.92M | +2.9% |
| Operating income | $700.39M | $324.17M | $383.96M | $431.30M | $310.81M | +116.1% |
| Net interest income | $37.54M | $33.12M | $30.17M | $26.19M | $24.54M | +13.3% |
| Pre-tax income | $751.51M | $343.60M | $389.94M | $482.31M | $558.01M | +118.7% |
| Tax provision | $165.91M | $40.27M | $90.66M | $58.14M | $153.01M | +312.0% |
| Net income | $585.61M | $303.33M | $299.28M | $424.17M | $405.00M | +93.1% |
| Net income to common | $585.61M | $303.33M | $299.28M | $424.17M | $405.00M | +93.1% |
| Basic EPS | 2.92 | 1.52 | 1.52 | 2.17 | 2.09 | +92.1% |
| Diluted EPS | 2.81 | 1.47 | 1.46 | 2.11 | 2.04 | +91.2% |
| EBIT | $752.10M | $344.17M | $390.52M | $482.90M | $558.61M | +118.5% |
| EBITDA | $778.57M | $367.97M | $414.50M | $506.92M | $581.52M | +111.6% |
| Basic shares | 200.38M | 199.34M | 197.44M | 195.67M | 194.00M | +0.5% |
| Diluted shares | 208.22M | 206.83M | 204.77M | 201.43M | 198.74M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.98B | $3.46B | $3.10B | $2.46B | $1.95B | +15.1% |
| Cash & short-term investments | $4.54B | $4.02B | $3.58B | $2.93B | $2.42B | +12.9% |
| Accounts receivable | $1.13B | $1.05B | $1.02B | $895.89M | $842.89M | +7.0% |
| Inventory | $112.54M | $115.62M | $101.06M | $83.45M | $83.42M | -2.7% |
| Total current assets | $6.03B | $5.48B | $5.02B | $4.28B | $3.64B | +9.9% |
| Property, plant & equipment | $735.03M | $746.84M | $758.40M | $826.79M | $827.54M | -1.6% |
| Goodwill & intangibles | $236.20M | $243.16M | $250.13M | $275.01M | $282.01M | -2.9% |
| Total assets | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | +7.3% |
| Total current liabilities | $1.31B | $1.49B | $1.52B | $1.34B | $1.28B | -11.9% |
| Total debt | $38.27M | $39.43M | $40.41M | $41.27M | $42.41M | -2.9% |
| Total liabilities | $1.53B | $1.72B | $1.79B | $1.68B | $1.65B | -11.0% |
| Retained earnings | $1.10B | $517.10M | $213.77M | -$85.51M | -$509.68M | +113.2% |
| Shareholder equity | $6.34B | $5.62B | $5.17B | $4.65B | $4.17B | +12.8% |
| Working capital | $4.71B | $3.99B | $3.51B | $2.94B | $2.37B | +18.0% |
| Net tangible assets | $6.11B | $5.38B | $4.92B | $4.38B | $3.89B | +13.5% |
| Shares issued | 200.98M | 199.95M | 198.46M | 196.13M | 194.12M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $585.61M | $303.33M | $299.28M | $424.17M | $405.00M | +93.1% |
| Depreciation & amortisation | $26.48M | $23.80M | $23.98M | $24.02M | $22.92M | +11.2% |
| Stock-based compensation | $67.26M | $64.13M | $62.16M | $61.60M | $64.61M | +4.9% |
| Change in working capital | -$281.61M | -$91.34M | $103.20M | -$60.42M | -$582.96M | -208.3% |
| Operating cash flow | $507.66M | $369.35M | $543.30M | $559.39M | $44.74M | +37.4% |
| Capital expenditure | -$12.41M | -$15.20M | -$21.88M | -$39.75M | -$19.07M | +18.3% |
| Investing cash flow | -$51.79M | -$88.20M | -$37.42M | -$47.42M | -$18.87M | +41.3% |
| Share buybacks | — | — | $0 | $0 | — | — |
| Financing cash flow | $65.46M | $84.82M | $137.74M | -$12.78M | -$11.25M | -22.8% |
| Free cash flow | $495.25M | $354.15M | $521.42M | $519.64M | $25.67M | +39.8% |
| End cash position | $3.98B | $3.46B | $3.10B | $2.46B | $1.96B | +15.1% |
Options analytics
Put / call volume
1.42
Put-heavy session
Put / call open interest
0.59
Positioning, not flow
Max pain
125.00
+10.9% from spot
ATM implied vol
51.6%
Nearest strike to spot
Skew (10% OTM)
-0.1%
Calls bid over puts
Call volume
38
Contracts, this expiry
Put volume
54
Contracts, this expiry
Heaviest call OI
140.00
677 contracts
Heaviest put OI
115.00
633 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.15 | 3.09 | +44.0% |
| Mar 2026 | 1.34 | 1.81 | +35.1% |
| Dec 2025 | 1.92 | 1.80 | -6.1% |
| Sep 2025 | 1.64 | 2.26 | +38.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -3.63 | 16 | $1.47B | +7.9% |
| Next quarter | 1.93 | 17 | $1.52B | +1.2% |
| Current year | 3.29 | 19 | $5.94B | +15.5% |
| Next year | 8.75 | 21 | $6.25B | +5.3% |
Analyst targets & ownership
Mean target$128.92
High target$157.00
Low target$86.00
Implied upside14.36%
Analyst count24
ConsensusBUY
Strong buy / Buy2 / 10
Hold15
Sell / Strong sell1 / 0
Held by insiders1.85%
Held by institutions103.43%
Institutions holding1.28K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
120.16
-6.19% from price
SMA 20
122.28
-7.81% from price
SMA 50
123.43
-8.67% from price
SMA 100
115.12
-2.08% from price
SMA 200
107.02
+5.34% from price
EMA 12
119.41
-5.60% from price
EMA 26
121.62
-7.31% from price
EMA 50
120.95
-6.79% from price
RSI (14)
30.1
Neutral
MACD (12,26,9)
-2.20
Hist -1.45
ATR (14)
3.34
2.96% of price
Realised vol 30D
25.1%
Annualised
Bollinger upper
130.53
20, 2σ
Bollinger lower
114.03
20, 2σ
50 / 200 cross
Golden
123.43 vs 107.02
Trend bias
Above 200
+5.34%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.43
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
25.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-18.3%
Peak to trough
Max drawdown 5Y
-40.5%
Peak to trough
ATR 14
3.34
2.96% of price
Beta (reported)
0.74
5Y monthly, from filing
Short interest
Shares short
9.98M
Prior 9.39M
Change vs prior
+6.3%
Shorts adding
% of float
8.39%
Normal
% of shares out
4.92%
Against total outstanding
Days to cover
7.6
Crowded exit
Float
170.41M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | Stifel | MAINTAINED | Buy | Buy |
| Oct 1, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Sep 28, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Sep 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 22, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Aug 20, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Aug 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 17, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 4, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 3, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Aug 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 29, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split2:1
Split dateSep 1, 2000
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-31
Periodic Financial Reports
10-Q · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-07-06
Corporate Changes & Voting Matters
8-K · 2026-06-22
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-06-08
Proxy Statements
DEFA14A · 2026-05-27
Annual Report to Shareholders
ARS · 2026-04-28
Headlines
Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
GlobeNewswire · 16h ago
Stifel Adjusts Price Target on Incyte to $157 From $145, Keeps Buy Rating
MT Newswires · 2d ago
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
StockStory · 5d ago
Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating
MT Newswires · 6d ago
INCY or TECH: Which Is the Better Value Stock Right Now?
Zacks · 7d ago
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Zacks · 9d ago
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
Zacks · 9d ago
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
Benzinga · 9d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.